The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

Patients with epidermal growth factor receptor (EGFR) exon 21 L858R substitution benefit less from standard EGFR tyrosine kinase inhibitor (TKI) treatment, and whether anti-angiogenic therapy was beneficial to the EGFR L858R subpopulation was inconclusive. A retrospective study was conducted to inve...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Liangkun, Zheng, Xinnan, Deng, Danchen, Pan, Hongming, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418331/
https://www.ncbi.nlm.nih.gov/pubmed/36028744
http://dx.doi.org/10.1038/s41598-022-18889-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418331/
https://www.ncbi.nlm.nih.gov/pubmed/36028744
http://dx.doi.org/10.1038/s41598-022-18889-z

Ejemplares similares